2 months ago
1
Sun Pharmaceutical, Dr. Reddy’s Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals rolled retired generic versions of Semaglutide connected March 21, pursuing the expiration of the patent connected the progressive constituent successful Danish large Novo Nordisk’s blockbuster diabetes and value nonaccomplishment drugs, Wegovy and Ozempic, successful India.
They joined Natco Pharma and 1 of its selling partners, Eris Lifesciences, which connected March 20 announced that their merchandise would beryllium disposable connected the archetypal time of the patent expiry. The generic drugmakers, with galore much expected to marque announcements, are eyeing a stock of the marketplace for Semaglutide successful India, which is estimated to beryllium $1 cardinal implicit the adjacent mates of years.
Driving the assurance of the companies are studies that estimation the fig of radical successful India with diabetes to beryllium much than 100 million, on with an further 136 cardinal who are pre-diabetic.
Pricing astatine a fraction of the innovator’s merchandise is the cardinal constituent for the companies arsenic they rotation retired generic Semaglutide, which belongs to the GLP-1 receptor agonists people of medication, to dainty benignant 2 diabetes mellitus and obesity, depending connected the approvals they person got from India’s cause regulator.
A enactment squad from Dr. Reddy’s Laboratories that spoke connected the motorboat of the company’s Semaglutide injection, Obeda, for Type 2 diabetes stated that the merchandise is disposable successful 2 mg and 4 mg strengths and comes successful a pre-filled, disposable format for subcutaneous, once-a-week medication with a user-friendly pen device. Each pen successful some strengths volition present a minimum of 4 play doses. The outgo to the diligent volition beryllium ₹4,200 per period for some strengths.
CEO of Branded Markets (India and Emerging Markets) M.V. Ramana, to a query, said Dr. Reddy’s pricing is based connected a study. The institution is hopeful of receiving Drugs Controller General of India (DCGI) support for usage of the merchandise for value absorption wrong the adjacent fewer months.
API improvement and manufacturing arsenic good arsenic formulation development, were conducted in‑house for Obeda, the elder executives said, adding the institution is besides eyeing markets abroad, specified arsenic Canada, Brazil and Russia for the merchandise arsenic they unfastened up.
Announcing the motorboat of its semaglutide injection nether the marque names Noveltreat and Sematrinity successful India, successful antithetic strengths, Sun Pharmaceutical said that the merchandise is priced importantly little than the innovator brand. The play therapy costs, from initiation to the highest dose, scope from astir ₹900 to ₹2,000 for Noveltreat, which is indicated for chronic value management, and from ₹750 to ₹1,300 for Sematrinity, which is indicated for the attraction of benignant 2 diabetes.
Zydus Life Sciences has launched semaglutide injection nether the marque names Semaglyn, Mashema, and Alterme, pursuing DCGI support for the manufacturing and selling of the merchandise for the attraction of diabetes and obesity. The institution stated that the injection volition beryllium disposable successful a 15 mg/3 ml cartridge, and the mean monthly outgo of attraction volition beryllium astir ₹2,200.
Glenmark Pharmaceuticals announced that it is launching Glipiq (semaglutide) for diabetes, aft support from the Central Drugs Standard Control Organization (CDSCO). The expected play outgo of attraction with the vials ranges from ₹325 to ₹440, the institution said.
